F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase

Related Keywords

Japan ,Canada ,United States ,Switzerland ,America ,Sabine Borngr ,Nathalie Altermatt ,Bruno Eschli ,Gerard Tobin ,Loren Kalm ,Birgit Masjost ,Levi Garraway ,Drug Administration ,World Health Organization ,Roche Group ,Roche Group Media Relations ,Genentech ,Head Of Global Product Development ,European Commission ,Health Canada ,European Medicines Agency ,Medicinal Products ,Human Use ,Chief Medical Officer ,Global Product ,New England Journal ,Fixed Duration Columvi ,Biologics License Application ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,World Health ,Cancer Incidence ,Refractory Diffuse Largeb Cell ,Hoffmann ,Oche ,Thmp ,Ecommends ,Approval ,Ixed ,Uration ,Columvi ,Glofitamab ,People ,Relapsed ,Refractory ,Diffuse ,Barge ,Fell ,Lymphoma ,